13F-HR filed by Saturn V Capital Management LP
Saturn V Capital Management LP filed this 13F-HR for the quarter ended 2026-06-30, filed 2026-08-14, with 23 holding rows worth $697,467,372.
- Accession
- 0001964437-26-000012
- Filer
- CIK 1964437
- Filed
- 2026-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2026
A holdings report, 23 entries on the cover page, a total value of $697,467,372 stated on the cover page (in dollars after the unit check, H1), rows summing to $697,467,372 with VALUE read as dollars as filed, 13F file number 028-22863. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 4,624,101 | $83,048,854 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 2,915,443 | $82,040,566 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 518,865 | $69,143,950 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 852,914 | $49,579,891 | dollars as filed | |
| IMMIX BIOPHARMA INC | 45258H106 | COMMON STOCK | 4,658,429 | $48,028,403 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 1,314,122 | $45,442,339 | dollars as filed | |
| JAZZ PHARMACEUTICALS PLC SHS USD | G50871105 | Stock | 160,938 | $38,781,230 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 370,318 | $38,742,669 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 524,730 | $38,378,752 | dollars as filed | |
| CANDEL THERAPEUTICS INC | 137404109 | COMMON STOCK | 3,303,686 | $34,027,966 | dollars as filed | |
| X4 PHARMACEUTICALS INC | 98420X202 | COMMON STOCK | 6,973,343 | $32,565,512 | dollars as filed | |
| MONOPAR THERAPEUTICS INC | 61023L207 | COMMON STOCK | 311,976 | $28,885,858 | dollars as filed | |
| DYNE THERAPEUTICS INC COM | 26818M108 | Stock | 1,057,493 | $23,486,920 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 1,052,043 | $19,620,602 | dollars as filed | |
| ZURA BIO LTD | G9TY5A101 | COMMON STOCK | 2,101,119 | $12,396,602 | dollars as filed | |
| SAGIMET BIOSCIENCES INC A | 786700104 | COMMON STOCK | 1,479,918 | $11,439,766 | dollars as filed | |
| OCULIS HOLDING AG | H5870P102 | CMN | 684,880 | $9,499,286 | dollars as filed | |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 3,869,056 | $7,854,184 | dollars as filed | |
| VIR BIOTECHNOLOGY INC | 92764N102 | COM | 770,643 | $7,852,852 | dollars as filed | |
| INVIVYD INC | 00534A102 | COMMON STOCK | 8,392,288 | $7,321,432 | dollars as filed | |
| ALTO NEUROSCIENCE INC COM SHS | 02157Q109 | Stock | 182,829 | $4,824,857 | dollars as filed | |
| SATELLOS BIOSCIENCE INC | 80401L803 | COM | 350,000 | $2,721,250 | dollars as filed | |
| OVID THERAPEUTICS INC | 690469101 | COMMON STOCK | 663,060 | $1,783,631 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001964437-26-000012 | this filing | 2026-08-14 | acceptance time not in the bulk data set |